{
    "2019-07-21": [
        [
            {
                "time": "",
                "original_text": "凯莱英：定增助力长期发展，API+制剂一体化、生物CDMO战略稳步推进",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "定增",
                        "长期发展",
                        "API",
                        "制剂一体化",
                        "生物CDMO"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "详解2019Q2机构医药持仓，继续推荐2+X主线",
                "features": {
                    "keywords": [
                        "2019Q2",
                        "机构医药持仓",
                        "2+X主线"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}